Current views on the pathogenesis of depression and approaches to antidepressive therapy (in case of coaxil)

Cite item

Full Text


The review considers the current theories of depression and its clinical manifestations, as well as the factors that determine the likelihood of depression. It presents information on cerebral structural and functional changes observed in depression. There are data on the tactics of antidepressive therapy as a whole and on the use of coaxil in particular.


  1. Kessler R. C., McGonagle K. A., Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry. 1994; 51: 8-19.
  2. Kasper S., McEven B. S. Neurobiological and clinical effects of the antidepressant tianptine. CNS Drugs 2008; 22 (1): 15- 26.
  3. Мосолов С. Н. Клинико-фармакологические свойства современных антидепрессантов. Психиатр. и психофармакотер. 2002; прил. № 1: 3-7.
  4. Danlop B. W., Nemeroff C. B. The role of dopamine in the pathophysiology of depression. Arch. Gen. Psychiatry 2007; 64: 327.
  5. Hirschfeld R. M. History and evolution of the monoamine hypothesis of depression. J. Clin. Psychiatry 2000; 61 (suppl. 6): 4-6.
  6. Pinder R. M. On the feasibility of designing new antidepressants. Hum. Psychopharmacol. 2001; 16: 53-59.
  7. Hindmarch I. Beyond the monoamine hypothesis: mechanisms, molecules and methods. Eur. Psychiatry 2002; 17 (suppl. 3): 294-299.
  8. van Praag H. M. Can stress cause depression. Progr. Neuropsychopharmacol. Biol. Psychiatry 2004; 28: 891-907.
  9. McEven B. S., Chattarji S. Molecular mechanisms of neuroplasticity and pharmacological implications: the example of tianeptine. Eur. Neuropsychopharmacol. 2004; 14 (suppl. 5): S497-S502.
  10. Aberg N. D., Brywe K. G., Isgaard J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration, and functionalplasticity in the adult brain. Sci. Wld J. 2006; 6: 53-80.
  11. Duman R. S., Montegia L. S. A neurotrophic model for stressrelated mood disorders. Biol. Psychiatry 2006; 59 (12): 1116- 1127.
  12. Duman R. S. Neuronal plasticity: consequensces of stress and actions of antidepressant treatment. Dialog. Clin. Neurosci. 2004; 6 (2): 157-169.
  13. Sheline Y. I., Mittler B. L., Mintum M. A. The hipocampus and depression. Eur. Psychiatry 2002; 17 (suppl. 3): 300-305.
  14. Kasper S. Neuroplasticity and the treatment of depression. Neuropsychiatr. Dis. Treat. 2006; 2 (S2): 14-20.
  15. Sheline Y. I., Sanghavi M., Mintum M. A. et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J. Neurosci. 1999; 19: 5034-5043.
  16. Bremer J. D., Vythilingam M., Vermetten E. et al. Reduced volume of orbitolfrontal cortex in major depression. Biol. Psychiatry 2002; 51: 273-279.
  17. Cotter D., Mackay D., Landau S. et al. Reduced glial cell dencity and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch. Gen. Psychiatry 2001; 58: 545-553.
  18. Rajkowska G., Miguel-Hidalgo J. J., Wei J. et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol. Psychiatry 1999; 45: 1085-1098.
  19. Ongur D., Drevets W. C., Price J. L. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc. Natl. Acad. Sci. USA 1998; 95: 13290-13295.
  20. Hamidi M., Drevets W. C., Price J. L. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol. Psychiatry 2004; 55: 563-569.
  21. Dreverts W. C. Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Progr. Brain Res. 2000; 126: 413-431.
  22. Dreverts W. C., Price J. L., Bardgett M. E. et al. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma Cortisol levels. Pharmacol. Biochem. Behav. 2002; 71 (3): 431-447.
  23. Mac Queen G. M., Campbell S., McEven B. S. et al. Course of illness, hippocampal function, and hippocampal volume in major depression. Proc. Natl. Acad. Sci. USA 2003; 100: 1387-1392.
  24. Frodl T., Meizenzahl E. M., Zetzsche T. et al. Hippocampal changes in patients with a first episode of major depression. Am. J. Psychiatry 2002; 159: 1112-1118.
  25. Frodl T., Meizenzahl E. M., Zetzsche T. et al. Enlargement of the amygdale in patients with a first episode of major depression. Biol. Psychiatry 2002; 51: 708-714.
  26. McEven B. S. Mood disorders and alostatic load. Biol. Psychiatry 2003; 54: 200-207.
  27. Bremer J. D., Narayan M., Andersen E. R. et al. Hippocampal volume reduction in major depression. Am. J. Psychiatry 2000; 157: 115-118.
  28. Sheline Y. I., Gado M. H., Price J. L. Amygdala core nuclei volumes are decreased in recurrent major depression. NeuroReport 1998; 9: 2023-2028.
  29. Von Gunten A., Fox N. C., Cipolotti L. et al. A volumetric study of hippocampus and amygdala in depressed patients with subjective memory problems. J. Neuropsychiatry Clin. Neurosci. 2000; 12: 493-498.
  30. Campbell S., Marriott M., Nahmias C. et al. Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am. J. Psychiatry 2004; 161: 598-607.
  31. Sheline Y. I., Wang P. W., Gado M. H. et al. Hippocampal atrophy in recurrent major depression. Proc. Natl. Acad. Sci. USA 1996; 93: 3908-3913.
  32. Erecinska M., Silver J. A. Metabolism and role of glutamate in mammalian brain. Progr. Neurobiol. 1990; 35 (4): 245-296.
  33. Zarate Jr. S. A., Du J., Quiroz J. et al. Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of glutamatergic system. Ann. N. Y. Acad. Sci. 2003; 1003: 273-291.
  34. Lowy M. T., Gault M. T., Yamamoto B. K. Adrenalectomy attenuates stress-induced elavations in extracellulars glutamate concentrations in the hippocampus. J. Neurochem. 1993; 61: 1957-1560.
  35. Lowy M. T., Wittenberg L., Yamamoto B. K. Effects of acute stress on hippocampal glutamate levels and spectrin proteolysis in young and age rats. J. Neurosci. 1995; 65: 268-274.
  36. Reznikov L. R., Grillo C. A., Piroli G. G. et al. Acute stress-mediated increased in extracellular glutamate levels in the rat amygdala: differentional effects of antidepressant treatment. Eur. J. Neurosci. 2007; 25 (10): 3109-3114.
  37. Yamamoto B. K., Regan L. P. The glutamatergic system in neuronal plasticity and vulnerability in mood disorders. Neuropsychiatr. Dis. Treat. 2006; 2 (suppl. 2): 7-13.
  38. McEven B. S., Sapolsky R. M. Stress and cognetive function. Curr. Opin. Neurobiol. 1995; 5: 205-216.
  39. Kim J. S., Schmid-Burgk W., Claus D. et al. Increased serum glutamate in depressed patients. Arch. Psychiatr. Nervenkr. 1982; 232: 229-304.
  40. Altamura C. A., Mauri M. C., Ferrara A. et al. Plasma and platelet excitatory amino acids in psychiatric disorders. Am. J. Psychiatry 1993; 150: 1731-1733.
  41. Altamura C., Maes M., Dai O. et al. Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression. Eur. Neuropsychopharmacol. 1995; 5 (suppl. 1): 71-75.
  42. Levine J., Panchalingam K., Rapoport A. et al. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol. Psychiatry 2000; 47: 1835-1853.
  43. Auer D. P., Putz B., Kraft E. et al. Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol. Psychiatry 2000; 47: 305-313.
  44. Mirza Y., Tang J., Russel A. et al. Reduced anterior cingulate cortex glutamatergic concentrations in childhood major depression. J. Am. Acad. Child Adolesc. Psychiatry 2004; 43: 341-348.
  45. Sanacora G., Gueorguieva R., Epperson C. N. et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 2004; 61: 705-713.
  46. Choudary P. V., Molnar M., Evans S. J. et al. Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc. Natl. Acad. Sci. USA 2005; 102: 15653-15658.
  47. Van der Hart M. G., Czeh B., de Biurrun G. et al. Substance P receptor antagonist and clomipramine prevent stress-induced alterations in cerebral metabolites, cytogenesis in the dentate gyrus and hippocampal volume. Mol. Psychiatry 2002; 7: 493-498.
  48. Wood G. E., Young L. T., Reagan L. P. et al. Stress-induced structural remodeling in hippocampus: prevention by lithium treatment. Proc. Natl. Acad. Sci. USA 2004; 101: 3973-3978.
  49. McEven B. S., Olie J. P. Neurobiology of mood, anxiety, and emotions as revealed by studies of a unique antidepressant: tianeptane. Mol. Psychiatry 2005; 10 (6): 525-537.
  50. McEven B. S., Magarinos A. M., Reagan L. P. Structural plasticity and tiaptine: cellular and molecular targets. Eur. Psychiatry 2002; 17 (suppl. 3): 318-330.
  51. Kole M. H., Swan L., Fuchs E. The antidepressant tianeptine persistently modulates glutamate receptor currents of the hippocampal CA3 commissural associational synapse in chronically stressed rats. Eur. J. Neurosci. 2002; 16: 807-816.
  52. Regan L. P., Rossel D. R., Wood G. E. et al. Chronic restraint stress up-regulates GLT-1 mRNA and protein expression in the rat hippocampus: reversal by tianeptine. Proc. Natl. Acad. Sci. USA 2004; 101: 2179-2184.
  53. Watnabe Y., Gould E., Cameron H. A. et al. Tianeptine attenuates stress-induced morthological changes in the hippocampus. Eur. J. Pharmacol. 1992; 222: 157-162.
  54. Lucassen P. J., Fuchs E., Czeh B. Antidepressant treatment with tianeptine reduces apoptosis in the hippocampal denate gyrus and temporal cortex. Biol. Psychiatry 2004; 55: 789-796.
  55. Kasper S., Olie J. P. A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur. Psychiatry 2002; 17 (suppl. 3): 331-340.
  56. Guelfi J. D., Pichot P., Dreyfus J. F. Efficacy of tianeptine in anxious-depressed patients: results of a controlled multicentre study versus amitriptyline. Neuropsychobiology 1989; 22 (1): 41-48.
  57. Invernizzi G., Aguglia E., Bertolino A. et al. The efficacy and safety of tianeptine in the treatment of depressive disorder: results of a controlled double-blind multicentre study vs. amitriptyline. Neuropsychobiology 1994; 30 (2-3): 85-93.
  58. Loo H., Malka R., Defrance R. et al. Tianeptine and amitriptyline: controlled double-blind trial in depressed alcoholic patients. Neuropsychobiology 1988; 19 (2): 79-85.
  59. Annseau M., Bataille M., Briole G. et al. Controlled comparison of tianeptine, alprazolam and mianserin in the treatment of adjustment disorders with anxiety and depression. Hum. Psychopharmacol. 1996; 11: 293-298.
  60. Brion S., Audrain S., de Bodinat C. Major depressive episodes in patients over 70 years of age: evaluation of the efficiency and acceptability of tianeptine and mianserin. Presse Med. 1996; 25 (9): 461-468.
  61. Alby J. M., Ferreri M., Cabane J. et al. Efficacy of tianeptine (StablonTM) for the treatment of major depression and dysthymia with somatic complaints: a comparative study versus fluoxetine (ProzacTM). Ann. Psychiatr. 1993; 8 (2): 136-144.
  62. Loo H., Saiz-Ruiz J., Costa e Silva J. et al. Efficacy and safety of tianeptine in the treatment of depressive disorders in comparison with fluoxetine. J. Affect. Disord. 1999; 56 (2-3): 109-118.
  63. Novotny V., Faltus F. First signs of improvement with tianeptine in the treatment of depression: an analysis of a double-blind study versus fluoxetine. Eur. Neuropsychopharmacol. 2003; 13 (suppl. 4): S230.
  64. Иванец Н. Н., Тювина Н. А., Балабанова В. В., Прупис О. В. Эффективность тианептина (коаксила) при депрессивных расстройствах невротического и субпсихотического уровня. Психиатр. и психофармакотер. 2002; прил. № 1: 7-9.
  65. Мосолов С. Н., Вовин Р. Я., Пантелеева Г. П. и др. Клиническая эффективность и переносимость препарата "Коаксил" (тианептин) при терапии депрессии. Журн. неврол. и психиатр. 2003; 8: 29-34.
  66. Тювина Н. А., Балабанова В. В. Место коаксила в терапии депрессивных расстройств климактерического периода у женщин. Психиатр. и психофармакотер. 2002; прил. № 1: 11-14.
  67. Нуллер Ю. Л., Жарницкая Д. З., Ишукова Л. В. Лечение коаксилом депрессии у больных пожилого возраста. Психиатр. и психофармакотер. 2002; прил. № 1: 9-11.
  68. Dalery J., Dagens-Lafont V., De Bodiant C. Efficacy tianeptine vs placebo in the long-term treatment (16.5 months) of unipolar major reccurrent depression. Hum. Psychopharmacol. 2001; 16 (suppl. I): S39-S47.
  69. Тювина Н. А., Крук Я. В. Сравнительное исследование эффективности амитриптилина, финлепсина и коаксила при профилактической терапии рекуррентного депрессивного расстройства. Психиатр. и психофармакотер. 2005; 3: 160-164.

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies